What are the side effects of Zoryve (roflumilast) topical cream or foam?

Side Effects of Zoryve (Roflumilast) Cream and Foam

The most common side effects of Zoryve vary by formulation and indication, but overall include diarrhea, headache, nausea, application site pain, and upper respiratory tract infections, with the medication demonstrating excellent tolerability and minimal serious adverse events. 1

Side Effects by Formulation and Indication

Zoryve Cream 0.3% (Plaque Psoriasis)

For adults and children ≥6 years treated for plaque psoriasis, the most common side effects include 1:

• Diarrhea
• Headache
• Trouble sleeping (insomnia)
• Nausea
• Application site pain
• Upper respiratory tract infections
• Urinary tract infections (UTIs)

Zoryve Cream 0.15% (Atopic Dermatitis)

For adults and children ≥6 years treated for atopic dermatitis 1:

• Headache
• Nausea
• Application site pain
• Diarrhea
• Vomiting

Zoryve Cream 0.05% (Atopic Dermatitis in Young Children)

For children 2-5 years treated for atopic dermatitis 1:

• Upper respiratory tract infections
• Diarrhea
• Vomiting
• Stuffy or runny nose
• Red or swollen eyes (conjunctivitis)
• Headache

Safety Profile from Clinical Trials

Long-term safety data demonstrates that roflumilast is exceptionally well-tolerated with minimal treatment discontinuations. In a 52-week open-label trial of roflumilast cream 0.3% for psoriasis, only 3.9% of patients discontinued due to adverse events and 0.9% due to lack of efficacy 2. Treatment-related adverse events occurred in only 3.6% of patients, with no serious treatment-related events reported 2.

Local Tolerability

• ≥97% of patients experienced no irritation in long-term studies 2
• ≤1.1% reported stinging sensation at the application site at each visit in extended trials 3
• No evidence of skin atrophy or tachyphylaxis with chronic use 2

Systemic Adverse Events

The overall incidence of adverse events was low across all formulations. Importantly, there was no significant difference in treatment-related adverse events, serious adverse events, or adverse events leading to discontinuation between roflumilast and vehicle groups 4.

Important Safety Considerations

Contraindications

• Do not use if you have certain liver problems 1
• Not for ophthalmic, oral, or intravaginal use 1

Special Populations

Pregnancy and Breastfeeding:

• Unknown if Zoryve will harm an unborn baby 1
• Unknown if Zoryve passes into breast milk 1
• Breastfeeding women should use on the smallest skin area for the shortest time needed 1
• Do not apply directly to nipple or areola to avoid infant exposure 1

Gastrointestinal Effects

While mild gastrointestinal symptoms (diarrhea, nausea) are common, they rarely cause discontinuation 5. In real-world studies of oral roflumilast for psoriasis, mild GI symptoms were reported but were generally well-tolerated 5.

Clinical Context

Unlike topical corticosteroids, roflumilast does not cause skin atrophy, striae, telangiectasia, or rebound phenomena 6. This represents a significant safety advantage for long-term use, particularly in sensitive areas like the face and intertriginous regions 2. The absence of tachyphylaxis means efficacy is maintained over time without requiring dose escalation 2.

The safety profile is particularly favorable compared to traditional topical therapies, with no need for laboratory monitoring and no serious systemic effects reported in clinical trials 5, 2.